Network pharmacology and computational-based approaches to activate NRF2 pathway via KEAP1 and GSK-3β inhibition: Exploring the possible molecular insights of mangiferin for Alzheimer's | Synapse
March 3, 2026
Network pharmacology and computational-based approaches to activate NRF2 pathway via KEAP1 and GSK-3β inhibition: Exploring the possible molecular insights of mangiferin for Alzheimer's
Key Points
Activation of the nrf2 pathway may offer neuroprotective benefits for Alzheimer's patients, indicating promising therapeutic avenues.
Significant inhibition of keap1 and gsk-3β was observed, hinting at a dual mechanism for enhancing nrf2 activity.
Analysis employing network pharmacology and computational methods elucidates the molecular workings of mangiferin in this context.
These findings support the need for future studies to explore mangiferin's benefits in Alzheimer's, though further clinical validations are necessary.